News | October 20, 2022

C4XD And HitGen To Collaborate In Inflammation Hit Identification Project

Initial project with option to expand collaboration on successful outputs

Chengdu /PRNewswire/ - C4X Discovery Holdings plc ("C4XD", AIM: C4XD), a pioneering Drug Discovery company, and Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH), a world leader in the development and application of DNA-encoded library (DEL) technology, today announce a research collaboration project to identify novel, small molecule hits against an inflammatory target for further C4XD development.

The aim of the project is to augment C4XD's growing pipeline of small molecule inflammatory disease candidates for pre-clinical development and out-licensing to the pharmaceutical industry. In this initial collaboration, C4XD and HitGen have together developed an approach for HitGen to apply its DEL screening technology platform to identify hits against a commercially valuable target for inflammatory diseases. If successful, C4XD will then apply its molecule design Conformetrix technology to translate these hits into suitable starting points for a small molecule programme, which can then be progressed through C4XD's rigorous Drug Discovery process. C4XD has the option to extend the collaboration with HitGen during this Drug Discovery phase to leverage HitGen's growing R&D capabilities.

Dr. Clive Dix, CEO of C4XD, said: "In line with our strategy to collaborate with innovative technology partners, C4XD extensively evaluates the small molecule discovery landscape and builds relationships with high potential complementary companies. We believe this collaboration with HitGen gives us access to a world-leading screening technology, which perfectly complements both our Drug Discovery expertise and Conformetrix technology and could enable C4XD to unlock a highly challenging target in inflammation. We are looking forward to working with their team and continuing to build on this exciting relationship."

Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen, said: "C4XD is a highly innovative company and has developed some very high-value assets using their proprietary Conformetrix technology. Combining their expertise with HitGen's world leading DNA-encoded library technology platform, we look forward to identifying good starting points for further development into valuable leads for the inflammatory target. We hope the collaboration could eventually turn into a strong partnership to deliver a number of solutions for highly unmet medical needs."

About C4X Discovery
C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world leading medicines, which are developed by our partners for the benefit of patients.

For further information, see our website:

About HitGen Inc.
HitGen Inc. (SSE: 688222.SH), is a drug discovery research company with headquarters in Chengdu, China, and subsidiaries in Cambridge, UK and Houston, USA. Our key technology platforms include DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD). .

For more information, please visit:

For business development:

Source: HitGen Inc.

Copyright 2022 PR Newswire. All Rights Reserved